Cantor Fitzgerald Raises Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target to $10.00

Rocket Pharmaceuticals (NASDAQ:RCKT) had its price objective increased by stock analysts at Cantor Fitzgerald from $8.00 to $10.00 in a note issued to investors on Friday,Benzinga reports. The firm currently has an “overweight” rating on the biotechnology company’s stock. Cantor Fitzgerald’s price target indicates a potential upside of 99.60% from the company’s previous close.

Other analysts have also recently issued research reports about the company. Morgan Stanley set a $5.00 price objective on Rocket Pharmaceuticals in a research note on Thursday, January 8th. JPMorgan Chase & Co. downgraded shares of Rocket Pharmaceuticals from a “neutral” rating to an “underweight” rating in a research report on Tuesday, November 18th. Wedbush reaffirmed an “outperform” rating and set a $16.00 price target on shares of Rocket Pharmaceuticals in a report on Friday, November 7th. Bank of America reduced their price objective on shares of Rocket Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating for the company in a report on Tuesday, November 18th. Finally, TD Cowen upgraded Rocket Pharmaceuticals to a “hold” rating in a research report on Friday, December 19th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have assigned a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $14.50.

Rocket Pharmaceuticals Price Performance

Shares of NASDAQ RCKT opened at $5.01 on Friday. The company has a quick ratio of 7.30, a current ratio of 7.30 and a debt-to-equity ratio of 0.06. Rocket Pharmaceuticals has a fifty-two week low of $2.19 and a fifty-two week high of $9.73. The business has a 50 day moving average price of $3.62 and a two-hundred day moving average price of $3.45. The firm has a market cap of $542.18 million, a PE ratio of -2.49 and a beta of 0.48.

Rocket Pharmaceuticals (NASDAQ:RCKT) last released its earnings results on Thursday, February 26th. The biotechnology company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.04. During the same period in the previous year, the firm earned ($0.62) EPS. Sell-side analysts expect that Rocket Pharmaceuticals will post -2.83 earnings per share for the current fiscal year.

Insider Activity at Rocket Pharmaceuticals

In other news, General Counsel Martin Wilson sold 12,253 shares of the firm’s stock in a transaction on Friday, February 13th. The stock was sold at an average price of $3.31, for a total value of $40,557.43. Following the completion of the sale, the general counsel owned 683,376 shares of the company’s stock, valued at $2,261,974.56. This trade represents a 1.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Gaurav Shah sold 12,279 shares of Rocket Pharmaceuticals stock in a transaction on Friday, February 13th. The shares were sold at an average price of $3.31, for a total value of $40,643.49. Following the transaction, the chief executive officer owned 1,052,045 shares in the company, valued at $3,482,268.95. This represents a 1.15% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 29,415 shares of company stock worth $97,398. Corporate insiders own 24.76% of the company’s stock.

Institutional Investors Weigh In On Rocket Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Prudential Financial Inc. acquired a new position in shares of Rocket Pharmaceuticals in the 2nd quarter valued at about $25,000. CANADA LIFE ASSURANCE Co grew its position in Rocket Pharmaceuticals by 94.4% during the second quarter. CANADA LIFE ASSURANCE Co now owns 12,202 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 5,926 shares in the last quarter. Corton Capital Inc. acquired a new position in Rocket Pharmaceuticals in the 2nd quarter valued at approximately $38,000. Franklin Resources Inc. purchased a new stake in Rocket Pharmaceuticals in the 4th quarter worth approximately $38,000. Finally, Virtu Financial LLC acquired a new stake in shares of Rocket Pharmaceuticals during the 3rd quarter valued at $40,000. 98.39% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Rocket Pharmaceuticals

Here are the key news stories impacting Rocket Pharmaceuticals this week:

• Positive Sentiment: Lifesci Capital upgraded RCKT to a “Strong-Buy” and issued a less-negative FY2026 EPS forecast of ($1.81) vs. the street consensus of ($2.83) — a sign analysts see smaller losses ahead and potential upside if pipeline progress continues. Lifesci upgrade & estimates
• Positive Sentiment: Cantor Fitzgerald raised its price target from $8 to $10 and reiterated an “Overweight” rating, implying substantial upside vs. the current share price and adding buying pressure from growth-focused investors. Cantor Fitzgerald raises PT to $10
• Positive Sentiment: Rocket reported a narrower-than-expected Q4 loss and provided pipeline updates — results that reduce near-term execution risk and keep focus on clinical catalysts that could drive future value. Q4 results & pipeline update
• Neutral Sentiment: Wall Street Zen moved its rating to “Hold,” signaling some caution remains among analysts despite recent positive notes. Wall Street Zen rating change
• Neutral Sentiment: Consensus analyst coverage still averages out to a “Hold,” so while a subset of firms are bullish, broad-market conviction is not unanimous. Analyst consensus summary

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing gene therapies for rare, inherited pediatric diseases. The company employs a proprietary adeno-associated virus (AAV) and lentiviral vector platform to deliver functional copies of genes in patients with genetic deficiencies. Its programs target a spectrum of disorders, including Fanconi anemia, leukocyte adhesion deficiency type I and Danon disease, with the goal of delivering one-time treatments that address the underlying causes of disease rather than merely managing symptoms.

The company’s pipeline comprises multiple product candidates in various stages of development.